Myricitrin　is　a　natural　occurring　flavonoid　glycoside　that　possesses　effects　on　inhibiting　nitric　oxide　(NO)　transmission　and　preventing　inflammatory　reaction.　Although　previous　study　showed　the　myricitrin　possesses　antibone　loss　effects　via　reducing　the　expression　of　IL-6　and　partially　suppressing　reactive　oxygen　species　(ROS)　production.　However,　the　effects　of　myricitrin　on　nuclear　factor-kappaB　ligand　(RANKL)-stimulated　osteoclastogenesis　have　not　yet　been　further　investigated.　The　current　study　was　aimed　to　demonstrating　the　inhibitory　effects　of　myricitrin　on　RANKL-stimulated　osteoclastogenesis　and　relevant　mechanisms.　We　found　myricitrin　significantly　suppressed　osteoclastogenesis　suggesting　that　it　may　acts　on　RANKL/RANK　induced　downstream　signal　cross　cascading　in　osteoclast　precursors.　In　that,　our　Western　blotting　results　showed　myricitrin　significantly　attenuated　RNAKL/MAPKs　(phosphorylation　of　p38,　ERK,　JNK)　and　AKT　signal　cascading.　Complementing　previous　study,　our　results　suggesting　as　a　natural　inhibitor,　myricitrin　possesses　the　potential　therapeutic　effects　on　inflammatory　osteolysis.